IL10 Specific Neutra™ Antibody Products

Are you struggling to target IL10-mediated immune dysregulation or facing challenges in developing high-affinity neutralizing antibodies? Creative Biolabs' IL10-specific neutra™ antibodies leverage advanced hybridoma screening and epitope mapping to deliver rigorously validated, high-specificity reagents, enabling precise modulation of IL10 signaling for accelerated drug discovery and functional research.

Introduction to IL10

Interleukin 10 (IL10), a pleiotropic cytokine primarily secreted by regulatory T cells, macrophages, and B cells, plays a critical role in suppressing pro-inflammatory responses and maintaining immune homeostasis. It modulates both innate and adaptive immunity by inhibiting antigen presentation, Th1 cytokine production, and macrophage activation. Dysregulated IL10 signaling is implicated in pathologies ranging from autoimmune diseases to cancer immune evasion.

• Structure

IL10 is a homodimeric protein composed of two 160-amino-acid subunits, each containing six α-helices arranged in a conserved helical bundle fold. The functional cytokine binds to its heterotetrameric receptor complex, comprising two IL10Rα chains for ligand engagement and two IL10Rβ chains for signal transduction. Structural studies reveal that the C-terminal domains of IL10 mediate receptor binding, while the N-terminal regions stabilize dimerization—a key feature for biological activity.

• Related Signaling Pathways

IL10 exerts immunosuppressive effects via JAK1/STAT3 activation. Upon binding to IL10Rα, the receptor-associated JAK1 kinases phosphorylate STAT3, which dimerizes and translocates to the nucleus to upregulate genes like SOCS3, suppressing pro-inflammatory cytokines (e.g., TNF-α, IL6). Concurrently, IL10 inhibits NF-κB and MAPK pathways, reducing dendritic cell maturation and T-cell activation.

Fig. 1 Immune modulatory signaling of IL10.¹

• Related Diseases

Overexpression of IL10 is linked to immunosuppression in tumor microenvironments, enabling cancer progression. Conversely, IL10 deficiency or receptor mutations correlate with hyperinflammatory conditions such as inflammatory bowel disease (IBD), psoriasis, and systemic lupus erythematosus (SLE). Therapeutic strategies targeting IL10 aim to either restore its anti-inflammatory function in autoimmune disorders or block its immunosuppressive activity in oncology.

Applications of Anti-IL10 Neutralizing Antibodies

• Therapeutic Intervention in Autoimmune Diseases

In rheumatoid arthritis and SLE, IL10 overexpression paradoxically sustains chronic inflammation by promoting regulatory B-cell survival. The neutralizing antibodies disrupt this feedback loop, reducing autoantibody production and restoring Th1/Th2 balance. Clinical trials using anti-IL10 agents show reduced disease activity scores in refractory IBD patients.

• Overcoming Tumor Microenvironment Immunosuppression

Tumor-associated macrophages secrete IL10 to suppress cytotoxic T-cell function and promote PD-L1 expression. Anti-IL10 antibodies synergize with checkpoint inhibitors, enhancing tumor infiltration by CD8⁺ T cells and improving response rates in preclinical melanoma and colorectal cancer models.

• Management of Chronic Inflammatory Disorders

In conditions like psoriasis, IL10 neutralization reduces keratinocyte hyperproliferation and TH17-driven inflammation. Antibody-based IL10 blockade also mitigates fibrosis in idiopathic pulmonary fibrosis by inhibiting fibroblast activation.

• Biomarker Development and Translational Research

IL10-neutralizing antibodies enable quantitative detection of bioactive IL10 in serum or tissue samples, aiding patient stratification in clinical trials. Their use in ELISA and multiplex assays support pharmacodynamic monitoring of IL10-targeted therapies.

Our Anti-IL10 Recombinant Antibody Products

Neutralizing anti-IL10 antibodies are indispensable tools for dissecting IL10's dual roles in immunity. Creative Biolabs IL10-specific antibodies exhibit picomolar affinity, validated through epitope binning and blockade of IL10-IL10Rα interactions. These antibodies are engineered for minimal cross-reactivity with homologous cytokines (e.g., IL19, IL20) and optimized for functional applications, including inhibition of STAT3 phosphorylation in vitro and in vivo. Preclinical studies demonstrate their efficacy in reversing IL10-mediated T-cell exhaustion and enhancing antitumor in mice models.

Creative Biolabs' IL10-specific neutra™ antibodies provide unmatched specificity and reproducibility for advancing research and therapeutic development. These antibodies are validated across ELISA, flow cytometry, and functional neutralization assays. Contact our team today to request custom validation data, bulk pricing, and tailored application support.

REFERENCE

1. Schülke, Stefan. "Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses." Frontiers in immunology 9 (2018): 455. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2018.00455